Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The recent report of an antisense oligonucleotide therapy designed for only one patient spotlights regulatory, economic and ethical issues that must be grappled with in an era of accelerated development of ‘ultra-personalized’ drugs.
The rise in cardiometabolic diseases is linked to the availability of unhealthy products from industry, such as ultraprocessed foods, and studying the efficacy of intervention strategies against these products must be high on the research agenda.
Nature Medicine is taking a comprehensive approach for reporting clinical studies with the aim to increase transparency, promote rigorous reporting standards and engage with the community to meet the challenges of contemporary medicine.
As the clinical potential of RNA therapeutics begins to be unveiled, expanding the range of tissue types that can be targeted for delivery of these drugs is now the main hurdle to overcome.
‘Precision’ in a health context is usually thought to apply to the individual and seems conceptually at odds with efforts in public health directed toward improving population-level health metrics. But are these two aims truly irreconcilable?
Recent measles outbreaks worldwide highlight the urgency of tracking and countering vaccine hesitancy to ensure the continued success of immunization programs.
The National Institutes of Health Human Microbiome Project is coming to a close, offering an opportunity to reflect on its legacy and the urgent need to understand the microbiome of underrepresented populations.
Immune interventions capable of preventing or eradicating HIV infection have yet to achieve broad success in humans. Renewed vigor in the clinical trial arena may bring us closer to that goal.
The use of electronic cigarettes is on the rise, but we need more evidence about their risks as well as their value in curbing tobacco use. Ultimately, we need to design better, smarter vaping tools for smoking cessation.
Cancer surveillance programs have reported a global downward trend in cancer mortality rates for most common tumor types. However, startling geographic inequalities exist, and some cancers continue to pose a challenge. Ensuring global access to high-quality diagnostic and treatment approaches is needed to make decreasing cancer deaths a more widespread trend.
As the world reckons with the news of the first use of genome editing in the human germline, researchers, clinicians, ethicists and policy makers must work across international boundaries to outline a transparent path forward for the responsible translation of this technology in the future.
As Nature Medicine celebrates its 25th anniversary, we bring you a special Focus on Digital Medicine that highlights the new technologies transforming medicine and healthcare, as well as the related regulatory challenges ahead.
